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Objectives: The resistance profiles of patients receiving long-term ART in sub-Saharan Africa have been poorly
described. This study obtained a sensitive assessment of the resistance patterns associated with long-term teno-
fovir-based ART in a programmatic setting where virological monitoring is yet to become part of routine care.
Methods: We studied subjects who, after a median of 4.2 years of ART, replaced zidovudine or stavudine with
tenofovir disoproxil fumarate while continuing lamivudine and an NNRTI. Using deep sequencing, resistance-
associated mutations (RAMs) were detected in stored samples collected at tenofovir introduction (T0) and after
a median of 4.0 years (T1).
Results: At T0, 19/87 (21.8%) subjects showed a detectable viral load and 8/87 (9.2%) had one or more major
NNRTI RAMs, whereas 82/87 (94.3%) retained full tenofovir susceptibility. At T1, 79/87 (90.8%) subjects
remained on NNRTI-based ART, 5/87 (5.7%) had introduced lopinavir/ritonavir due to immunological failure, and
3/87 (3.4%) had interrupted ART. Whilst 68/87 (78.2%) subjects maintained or achieved virological suppression
between T0 and T1, a detectable viral load with NNRTI RAMs at T0 predicted lack of virological suppression at T1.
Each treatment interruption, usually reflecting unavailability of the dispensary, doubled the risk of T1 viraemia.
Tenofovir, lamivudine and efavirenz selected for K65R, K70E/T, L74I/V and Y115F, alongside M184V and multiple
NNRTI RAMs; this resistance profile was accompanied by high viral loads and low CD4 cell counts.
Conclusions: Viraemia on tenofovir, lamivudine and efavirenz led to complex resistance patterns with implica-
tions for continued drug activity and risk of onward transmission.
Introduction
Access to ART has been increasing in sub-Saharan Africa (SSA),
where an estimated 25.5 million people live with HIV, of whom
36% (Western and Central Africa) to 61% (Eastern and Southern
Africa) were receiving treatment in 2016.1 WHO recommends a
public health approach to managing HIV in SSA, based upon rapid
treatment initiation regardless of CD4 cell counts, and use of
standardized regimens for first-line and second-line therapy.2
Recommended first-line regimens comprise two NRTIs with either
an NNRTI, principally efavirenz, or more recently with the integrase
inhibitor dolutegravir.2
Treatment programmes for SSA initially employed zidovudine
or stavudine, each typically combined with lamivudine, as first-line
NRTIs. In 2009, WHO recommended phasing out stavudine in fa-
vour of less-toxic NRTIs, including tenofovir disoproxil fumarate
(henceforth referred to as tenofovir).3 Current WHO guidelines
place tenofovir, in combination with lamivudine or emtricitabine,
as the preferred NRTI backbone for the treatment of HIV infection
in SSA, including the treatment of highly prevalent coinfection
with HBV.4 Use of tenofovir as part of ART has been increasing as a
result.5 In 2013, WHO also recommended that plasma viral load
monitoring should be adopted in SSA to guide treatment changes,
replacing reliance on CD4 cell counts and clinical indicators of
treatment failure.6 However, implementation of viral load moni-
toring varies across the region, and even in settings with access to
testing delays in identifying treatment failure are commonly
reported.7–10 HIV-positive individuals in SSA also face additional
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challenges: inconsistent drug supplies due to stock-out can lead to
unintended ART interruptions, and travel-related and other
costs of accessing care pose an obstacle to retention in regular
follow-up.11,12 In a meta-analysis of 163 studies, the observed
rates of virological suppression were 89% after 48 months of pre-
dominantly NNRTI-based first-line ART in SSA, declining to 62% in
the ITT analysis that excluded those who had died, were lost to fol-
low-up or had interrupted ART.13
The aim of this study was to determine the viral load and drug
resistance outcomes of first-line ART in a typical HIV programmatic
setting in SSA, where changes in the preferred NRTI backbone,
introduced to reflect updated guidelines, occurred without viro-
logical monitoring. Using stored samples from a separate pro-
spective study,14 viral load and drug resistance-associated
mutations (RAMs) were determined retrospectively to reflect
4 years of follow-up, and the findings were related to the self-
reported history of treatment interruptions and adherence.
Patients and methods
Study population
The study investigated HIV-1/HBV-positive adults receiving care at the
Komfo Anokye Teaching Hospital, a 1200 bed facility in the city of Kumasi
and the second-largest hospital in Ghana, serving a population of 4 million
people in the Ashanti Region. Recruitment into a prospective observational
cohort occurred in 2010–12, and the last observation took place in
November 2015. Given the observational nature of the study, management
between study visits was at the discretion of the treating clinician and re-
flective of routine care; testing for viral load and drug resistance was not
routinely available. Subjects eligible for this analysis were those that at
study entry (time zero, T0) replaced zidovudine or stavudine with tenofovir
while continuing lamivudine and the NNRTI (efavirenz or nevirapine), and
remained in care at the last study visit (T1). The disposition of all subjects is
shown in Figure S1 (available as Supplementary data at JAC Online). At
study visits, patients underwent clinical examination and blood sampling,
and available clinical and laboratory data were collected from the medical
records. Plasma samples were stored at #80C at T0, T1 and at least one
additional study visit between T0 and T1. At T1, participants were invited to
respond to a questionnaire about the number of times they had interrupted
ART for3 consecutive days since first starting treatment and in the previ-
ous 3 months. Adherence to ART in the previous 3 months was also deter-
mined at T1 using a visual analogue scale, which scored adherence from
0% (complete non-adherence) to 100% (complete adherence) in 10%
increments;15,16 optimal adherence was defined as a score90%.
Ethics
Ethics approval was granted by the Kwame Nkrumah University of Science
and Technology, Ghana (reference CHRPE/AP/347/15) and all participants
gave written informed consent. The study was conducted in accordance
with the Declaration of Helsinki and national and institutional standards.
Retrospective viral load and resistance testing
Plasma was separated from whole venous blood in EDTA within 1 h of col-
lection by centrifugation at 4500g for 5 min and stored at#80C. Samples
were shipped frozen to the UK for retrospective testing. Plasma HIV-1 RNA
was quantified by the RealTime HIV-1 assay (Abbott Diagnostics,
Maidenhead, UK) with a lower limit of quantification of 40 copies/mL.
Samples with detectable HIV-1 RNA underwent testing for the presence of
RAMs in reverse transcriptase (RT, amino acids 14–345) and protease
(amino acids 1–99) by Sanger sequencing, as described.17 Genotypic
susceptibility scores (GSSs) were determined using the Stanford HIV Drug
Resistance algorithm (v8.4): each drug in the regimen was assigned a score
of 0 for high-level resistance, 0.25 for intermediate resistance, 0.5 for low-
level resistance and 1 for potential low-level resistance or full predicted sus-
ceptibility. Patients that did not yield an amplicon for sequencing (all with
viral load ,200 copies/mL) were assigned a GSS of 3. Samples also under-
went deep sequencing using a method similar to one that has been previ-
ously described.18,19 Briefly, a 1000 bp RT amplicon was generated, purified
with the Agencourt Ampure XP system (Beckman Coulter, High Wycombe,
UK) and quantified with the Qubit dsDNA High Sensitivity Assay Kit using the
Qubit 3.0 fluorimeter (Invitrogen, Loughborough, UK). A DNA library was
prepared with the Nextera XT DNA Sample Prep Kit (Illumina, San Diego, CA,
USA), followed by sequencing with the MiSeq Reagent Kit v2. Consensus
sequences and frequencies of reads were produced as previously described;
reads were analysed applying a 1% interpretative cut-off.19,20 RAMs consid-
ered major in the resistance analysis are reported in Table S1.
Statistical analysis
Characteristics of participants at T0 versus T1 were compared by the
Wilcoxon matched-pairs/paired t-test or Fisher’s exact test. The prevalen-
ces of reported treatment interruptions and suboptimal adherence accord-
ing to viral load status at T1 were compared by the v2 test. Factors
associated with a detectable viral load at T1 were explored by univariable
logistic regression analysis. Variables included in the univariable analysis
comprised gender, age, viral load, CD4 cell count and presence of RAMs at
T0, and reported treatment interruptions and adherence at T1. A separate
model analysed factors associated with the combined outcome of showing
a detectable viral load at T0 or having introduced lopinavir/ritonavir be-
tween T0 and T1. A sensitivity analysis explored factors associated with a
detectable viral load at T1 by an ITT approach, including all subjects that
started tenofovir at T0 regardless of whether they remained in follow-up at
T1 (missing" failure). The relationship between viral load and CD4 cell
count at T1 was determined by univariable linear regression analysis.
Analyses were performed with STATA version 14 (StataCorp, College
Station, TX, USA).
Results
Treatment status at T1
The study population comprised 87 subjects that, after receiving zi-
dovudine or stavudine plus lamivudine and an NNRTI for a median
of 4.2 years (IQR 2.5–5.4), replaced zidovudine or stavudine with
tenofovir while continuing lamivudine and the NNRTI, in the ab-
sence of viral load testing (Table 1). After a median of 4.0 years
(IQR 3.8–4.1), 82/87 (94.3%) subjects continued on tenofovir plus
lamivudine and 79/87 (90.8%) remained on an NNRTI, with greater
efavirenz use in preference to nevirapine. A small number (5/87,
5.7%) had introduced ritonavir-boosted lopinavir. The remaining
3/87 (3.4%) subjects were no longer on ART, having interrupted
treatment 3 months, 2 years and 3 years prior to T1, respectively.
In the questionnaires, 28/87 (32.2%) respondents reported that
they had interrupted treatment for3 consecutive days since first
starting ART, although most (25/28) had subsequently resumed
treatment. Overall 9/87 (10.3%) subjects reported three or more
interruptions and 16/87 (18.4%) reported an interruption within
the previous 3 months. Reasons given for interrupting ART were pri-
marily temporary closure of the HIV dispensary and, less common-
ly, use of herbal remedies or misunderstanding instructions. By
visual analogue scale, 12/87 (13.8%) respondents reported adher-
ence,90% in the previous 3 months.
Drug resistance during tenofovir-based ART JAC
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Viral load and drug resistance-associated mutations at
T0 and T1
Retrospectively, across the whole population, 19/87 (21.8%) sub-
jects at T0 and 19/87 (21.8%) subjects at T1 had a viral load
.40 copies/mL (Table 1). The proportion with viral load .10000
copies/mL increased at T1 compared with T0 (14.9% versus 6.9%,
P" 0.14), whereas median CD4 cell count did not change signifi-
cantly between timepoints (558 versus 580 cells/mm3; P"0.47).
Reporting treatment interruptions and adherence levels ,90%
was significantly more prevalent among subjects with a
detectable viral load at T1 than in subjects with suppressed viral
load (Figure 1, Table S2).
At T0, 8/87 (9.2%) subjects had one or more major NNRTI RAMs
and 7/87 (8.0%) had one or more major NRTI RAMs (Table 1); most
subjects (82/87; 94.3%) showed full predicted susceptibility to
tenofovir. The median GSS of the tenofovir-containing regimen
started at T0 was 3 and the range was from 0.5 to 3. By logistic re-
gression analysis, showing a detectable viral load and RAMs at T0
and reporting treatment interruptions and suboptimal adherence
at T1 were each predictive of a detectable viral load at T1 (Table 2).
Table 1. Characteristics of the study population at the time of switching from zidovudine or stavudine to tenofovir disoproxil fumarate (T0) and after
a median of 4 years (T1) (n"87)
Characteristic T0 T1
Gender, female, n (%) 57 (65.5) 57 (65.5)
Age, years, median (IQR) 40 (34–44) 44 (39–48)
BMI, kg/m2, median (IQR) 24.0 (21.0–26.3) 23.2 (20.3–27.1)
Time from HIV diagnosis, years, median (IQR) 4.5 (3.2–6.3) 8.6 (7.2–10.3)
CD4 count at HIV diagnosis, cells/mm3, median (IQR) 185 (87–333) 185 (87–333)
CD4 cell count, cells/mm3, median (IQR) 580 (360–742) 558 (346–711)
Antiretroviral agent, n (%)
efavirenz 49 (56.3) 77 (88.5)
nevirapine 38 (43.7) 2 (2.3)
lopinavir/ritonavir 0 (0) 5 (5.7)
stavudine! lamivudine 13 (14.9) 0 (0)
zidovudine! lamivudine 74 (85.1) 2 (2.3)
tenofovir! lamivudine 0 (0) 82 (94.3)
none 0 (0) 3 (3.4)
Total ART duration, years, median (IQR) 4.2 (2.5–5.4) 8.1 (6.5–9.2)
Total tenofovir duration, years, median (IQR) 0 (0) 4.0 (3.8–4.1)
HIV-1 RNA copies/mL, n (%)
,40 68 (78.2) 68 (78.2)
40–399 9 (10.3) 5 (5.7)
1000–9999 4 (4.6) 1 (1.1)
.10000 6 (6.9) 13 (14.9)
RAMs, n (%)
any 8 (9.2) 11 (12.6)
NNRTI only 1 (1.1) 2 (2.3)
NRTI! NNRTI 7 (8.0) 9 (10.3)
PI 0 (0) 0 (0)
none 7 (8.0) 5 (5.7)
no amplicon 4 (4.6)a 2 (2.3)b
Treatment interruptionc, n (%)
0 – 59 (67.8)
1 or 2 – 19 (21.8)
3 – 9 (10.3)
Adherenced, n (%) – 54 (62.1)
100%
90% – 21 (24.1)
70%–80% – 9 (10.3)
off ART – 3 (3.4)
aFour samples with viral load 40–60 copies/mL did not yield an amplicon for sequencing in repeated attempts.
bTwo samples with viral 40–200 copies/mL did not yield an amplicon for sequencing in repeated attempts.
cDefined as interrupting ART for3 consecutive days since first starting treatment.
dMeasured by visual analogue scale.
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3150
D
ow
nloaded from
 https://academ
ic.oup.com
/jac/article-abstract/73/11/3148/5055837 by U
N
IVER
SITY O
F SU
SSEX LIBR
AR
Y user on 02 January 2020
Results were confirmed in two separate models considering (i) the
combined outcome of a detectable viral load at T0 or having intro-
duced lopinavir/ritonavir between T0 and T1, and (ii) adopting an
ITT approach that included patients who had died or were lost to
follow-up after T0 (not shown). At T1, by linear regression analysis,
CD4 cell counts were 135 cells/mm3 lower for each log10 increase
in viral load (95% CI 93–176; P,0.01).
Evolution of viral load and drug resistance
Four patterns were identified among subjects receiving an NNRTI
throughout follow-up: (i) 58/82 (70.7%) subjects had a suppressed
viral load at both T0 and T1; (ii) 8/82 (9.8%) subjects with detect-
able viral load at T0 achieved viral load suppression at T1; (iii) 8/82
(9.8%) subjects with suppressed viral load at T0 experienced viral
load rebound at T1; and (iv) 8/82 (9.8%) subjects had a detectable
viral load at both timepoints. Patient-level data are presented in
Tables 3–5, which also include the three subjects that had discon-
tinued ART at T1. Within viral load group (ii) (T0 detectable/T1 sup-
pressed; Table 3), most patients had viral load ,200 copies/mL at
T0 and all had a suppressed viral load at the next study visit after
T0 and prior to T1. In this group, one patient on tenofovir, lamivu-
dine and efavirenz showed the major NNRTI RAM K103N at T0; the
T0 viral load was 101 copies/mL and the patient reported no treat-
ment interruptions and 100% adherence. Within viral load group
(iii) (T0 suppressed/T1 detectable, Table 4), 5/8 patients showed
emergence of major RAMs at viral load rebound: all had the lamiv-
udine mutation M184V and two or more NNRTI RAMs and three
subjects had thymidine analogue mutations (TAMs). In addition,
three subjects on tenofovir, lamivudine and efavirenz showed one
or more discriminatory NRTI RAMs (RT codons 65, 70, 74, 115).
Within viral load group (iv) (T0 detectable/T1 detectable; Table 5),
4/8 subjects showed emergence of one or more discriminatory
NRTI RAMs (RT codons 65, 70, 74, 115), always alongside M184V
and with or without TAMs. In this group, between T0 and T1 the
number of NNRTI RAMs increased from a median of 0 (range 0–3)
to a median of 3 (range 0–4) and the median viral load increased
from 2.6 (IQR 1.7–3.7) to 4.3 (IQR 4.1–5.1) log10 copies/mL
(P"0.02), whereas the median CD4 count declined from 544 (IQR
368–590) to 215 (IQR 167–278) cells/mm3 (P"0.08). The profile
of the five subjects on lopinavir/ritonavir is shown in Table 6. The
patients had introduced lopinavir/ritonavir a median of 3.7 (IQR
1.1–3.9) years prior to T1 as a result of a decline in CD4 cell counts.
At T1, three subjects showed a detectable viral load, all at levels
,200 copies/mL; one subject on tenofovir plus lamivudine showed
discriminatory NRTI RAMs (RT codons 65, 70).
Overall, considering the entire population at risk, 8/87 (9.2%)
subjects on tenofovir developed one or more discriminatory NRTI
RAMs over a median of 4.0 years of exposure. Discriminatory NRTI
RAMs usually occurred at high frequency in each patient’s sample
and were therefore detected by both Sanger and deep sequencing.
Low-frequency (1%–5%) variants detected only by deep sequenc-
ing comprised K70E (n"1), L74I (n" 2), L74V (n"1) and Y115F
(n"1). Between T0 and T1, the number of NRTI and NNRTI RAMs
increased by five and six per year, respectively. At T1, prevalence of
predicted intermediate or high-level resistance to lamivudine or
emtricitabine, abacavir, tenofovir and zidovudine was 12/87
(13.8%), 10/87 (11.5%), 4/87 (4.6%) and 4/87 (4.6%) respectively.
Tenofovir and zidovudine resistance did not usually overlap.
Discussion
This study investigated the long-term viral load and drug resist-
ance outcomes of subjects accessing first-line NNRTI-based ART in
a programmatic setting in SSA, where implementation of virologic-
al monitoring has yet to take place. Focusing on subjects that
remained in care, the study found that at a median of 4 years after
first introducing tenofovir in place of zidovudine or stavudine, most
patients were still receiving tenofovir, lamivudine and efavirenz
and only a minority (5.7%) had started second-line ART with a
boosted PI as a result of immunological failure. While most
patients maintained or achieved viral load suppression during
follow-up, having a detectable viral load with evidence of NNRTI
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Figure 1. Proportion of subjects with suppressed (,40 copies/mL) or de-
tectable plasma HIV-1 RNA after a median of 8.1 years of ART according
to reported treatment interruptions and adherence. The number of sub-
jects with a detectable viral load is indicated in each column. A treat-
ment interruption was defined as interrupting ART for 3 consecutive
days since first starting treatment. Adherence was measured with a vis-
ual analogue scale.
Table 2. Univariate logistic regression analysis of factors associated with
a detectable plasma HIV-1 RNA (.40 copies/mL) after a median of
8.1 years of ART (T1, n"19)a
Variable OR 95% CI P value
Gender (female versus male) 0.38 0.13–1.06 0.07
Age (per 5 year increment) 1.01 0.74–1.38 0.96
T0 CD4 count (per 50 cells lower) 1.10 1.00–1.22 0.06
T1 CD4 count (per 50 cells lower) 1.51 1.24–1.84 ,0.01
T0 HIV-1 RNA (per 1 log10 copies/mL higher) 1.97 1.15–3.35 0.01
T0 NNRTI RAMs (yes versus no) 15.2 2.76–84.0 ,0.01
Treatment interruption (per interruption)b 2.32 1.41–3.82 ,0.01
Adherence (per 10% lower)c 2.10 1.19–3.70 0.01
aT0 variables were measured at the introduction of tenofovir and after a
median of 4.2 years of ART; T1 variables were measured a median of
4.0 years later.
bDefined as interrupting ART for 3 consecutive days since first starting
treatment.
cMeasured by visual analogue scale.
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resistance at the time of introducing tenofovir was predictive of a
lack of viral load suppression after 4 years. Notably, prior to intro-
ducing tenofovir, patients had received a thymidine analogue
(zidovudine or stavudine) with lamivudine for a median of
4.2 years, but the prevalence of TAMs was limited and most
patients retained full predicted susceptibility to tenofovir. Patients
who subsequently experienced viraemia while on tenofovir, lamiv-
udine and efavirenz acquired discriminatory NRTI RAMs, including
well-recognized tenofovir RAMs (K65R, K70E/T) as well as RAMs not
typically associated with tenofovir (L74I/V, Y115F), alongside
M184V and with or without TAMs. The complex mutation patterns
have uncertain effects on continued tenofovir susceptibility.
Importantly, there was no suggestion of impaired viral fitness
based on viral load and CD4 cell counts.
The observed high prevalence and progressive accumulation
of NNRTI RAMs among patients experiencing viraemia on NNRTI-
based ART is in line with other studies from SSA.21–30 We
observed interesting patterns of NRTI resistance associated with
tenofovir, lamivudine and efavirenz exposure in this cohort com-
prising predominantly CRF02 and CRF06 strains. Rhee et al.31 re-
cently compared RT sequences from subjects with virological
failure on a first-line tenofovir-containing regimen with
sequences from ART-naive patients and patients on thymidine
analogues. Overall, 12 mutations—A62V, K65R/N, S68G/N/D,
K70E/Q/T, L74I, V75L and Y115F—were statistically associated
with tenofovir exposure. It should be noted, however, that only
some of these (for example K65R and K70E) are recognized as
predicting reduced tenofovir susceptibility in commonly used re-
sistance interpretation algorithms. Our prospectively collected,
quantitative resistance data provide strength to the statistical
association reported by Rhee et al.31 L74I was common in our co-
hort. Whereas most RAMs occurred at high frequency, L74I also
occurred at a low frequency, below the detection limit of Sanger
sequencing. We observed co-occurrence of multiple discrimin-
atory mutations at codons 65, 70, 74 and 115, including co-
occurrence of K65R with L74I or K70T. L74V is known to rarely
coexist with K65R due to a marked fitness effect.32 In contrast,
the combination of K65R with L74I increases RT processivity and
viral replication is preserved.33 It has also been proposed that
L74I restores the fitness of variants with the NNRTI RAM
K103N.34 Taken together, the data indicate that selective pres-
sure by tenofovir, lamivudine and efavirenz drove viral genetic
evolution towards high drug resistance and preserved viral
fitness. Further studies are needed to determine the impact of
Table 3. Patients on efavirenz or nevirapine showing a detectable viral load at T0 and a suppressed viral load at T1a
RAMs
ID and
subtype Timepoint Regimen
ART
(years)
TDF
(years)
Viral load
(log10 copies/mL)
CD4 count
(cells/mm3) NRTI NNRTI GSS
029 CRF02 T0 D4T/3TC/NVP 0.5 0 5.5 278 none none 3
TDF/3TC/EFV 1.9 1.4 UD 507 – – 3
T1 TDF/3TC/EFV 4.5 4.0 UD 711 – – 3
050 CRF02 T0 ZDV/3TC/NVP 1.1 0 5.1 243 none none 3
TDF/3TC/EFV 2.5 1.3 UD 214 – – 3
T1 TDF/3TC/EFV 5.0 3.9 UD 293 – – 3
086 CRF02 T0 ZDV/3TC/EFV 3.3 0 1.8 689 none none 3
TDF/3TC/EFV 3.8 0.5 UD 849 – – 3
T1 TDF/3TC/EFV 7.4 4.1 UD 655 – – 3
130 CRF02 T0 D4T/3TC/EFV 4.0 0 2.3 225 none none 3
TDF/3TC/EFV 4.9 0.9 UD 504 – – 3
T1 TDF/3TC/EFV 8.2 4.2 UD 443 – – 3
147 CRF02 T0 ZDV/3TC/EFV 4.3 0 3.2 173 none none 3
TDF/3TC/EFV 4.7 0.5 UD ND – – 3
T1 TDF/3TC/EFV 7.7 3.4 UD 265 – – 3
216 A1 T0 ZDV/3TC/EFV 2.5 0 2.0 703 none K103N (96) 2
TDF/3TC/EFV 3.8 1.3 UD 494 – – 2
T1 TDF/3TC/EFV 6.4 3.9 UD 514 – – 2
003 T0 ZDV/3TC/EFV 5.0 0 1.7 580 no amplicon no amplicon 3
TDF/3TC/EFV 5.8 0.8 UD 588 – – 3
T1 TDF/3TC/EFV 9.1 4.1 UD 528 – – 3
115 T0 ZDV/3TC/EFV 1.8 0 1.8 159 no amplicon no amplicon 3
TDF/3TC/EFV 2.9 1.1 UD 259 – – 3
T1 TDF/3TC/EFV 5.2 3.4 UD 345 – – 3
UD, undetectable (,40 copies/mL); D4T, stavudine; 3TC, lamivudine; NVP, nevirapine; TDF, tenofovir disoproxil fumarate; EFV, efavirenz; ZDV,
zidovudine.
aRAMs were detected by both Sanger sequencing and deep sequencing. The frequency (%) of each RAM in the deep sequencing reads is reported in
parentheses.
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K70T, L74I/V and Y115F and the combination of multiple discrim-
inatory RAMs on phenotypic susceptibility and clinical responses
to tenofovir. We had insufficient samples to perform phenotypic
resistance testing in this cohort. Increasing rates of NNRTI resist-
ance in SSA are of concern, and it is expected that patients will
likely benefit from the planned introduction of the fixed-dose
combination of tenofovir, lamivudine and dolutegravir.35,36
However, efficacy in patients harbouring multiple discriminatory
mutations affecting tenofovir and in the context of the high di-
versity of viral strains circulating in SSA remains to be deter-
mined. Implementation should be accompanied by enhanced
efforts to establish virological monitoring and by public health
programmes to survey efficacy.
The observed rate of virological suppression was 78% after a
median of 4.2 years of NNRTI-based first-line ART, and in line with
published data from SSA.13 It is encouraging that the observed
suppression rate was maintained during a further 4 years of
follow-up. Previous systematic analyses have shown that taking
an ITT approach leads to lower suppression rates in SSA popula-
tions due to mortality and loss to follow-up, and this was also true
of our cohort.13 We have previously reported on the large varia-
tions in the rates of switching to second-line ART in SSA, with higher
Table 4. Patients on efavirenz or nevirapine showing a suppressed viral load at T0 and a detectable viral load at T1a
RAMs
ID and
subtype Timepoint Regimen
ART
(years)
TDF
(years)
Viral load
(log10 copies/mL)
CD4 count
(cells/mm3) NRTI NNRTI GSS
146 CRF02 T0 ZDV/3TC/EFV 4.3 0 UD 790 – – 3
TDF/3TC/EFV 4.9 0.6 UD 743 – – 3
T1 TDF/3TC/EFV 7.8 3.5 5.1 337 none none 3
188 CRF02 T0 ZDV/3TC/EFV 5.0 0 UD 452 – – 3
TDF/3TC/EFV 5.7 0.7 UD 732 – – 3
T1 TDF/3TC/EFV 9.0 4.0 5.3 172 none none 3
218 T0 ZDV/3TC/NVP 1.0 0 UD 214 – – 3
TDF/3TC/EFV 2.7 1.7 UD ND – – 3
T1 TDF/3TC/EFV 4.8 3.8 2.1 939 no amplicon no amplicon 3
010 CRF02 T0 ZDV/3TC/NVP 2.8 0 UD 758 – – 3
TDF/3TC/EFV 3.3 0.5 UD 823 – – 3
T1 ZDV/3TC/NVP 6.6 1.4 4.7 346 M184V (15) K103N (100)
P225Y (8) F227L (92)
1
030 CRF02 T0 ZDV/3TC/NVP 1.3 0 UD 256 – – 3
TDF/3TC/EFV 1.8 0.4 2.0 279 none none 3
TDF/3TC/EFV 2.5 1.1 2.1 294 none none 3
T1 TDF/3TC/EFV 5.3 4.0 5.7 8 L74I (5) M184I (14) K101E (30) K103N (100)
Y181C (19) G190A (20)
1
018 CRF02 T0 D4T/3TC/EFV 3.7 0 UD 672 – – 3
TDF/3TC/EFV 4.1 0.5 UD 273 – – 3
T1 TDF/3TC/EFV 7.8 4.1 4.7 14 K65R (97) D67N (81)
K70T (20) Y115F (99)
M184V (100) K219E (86)
K103N (99)
V108I (99)
Y181C (100)
0
099 CRF06 T0 ZDV/3TC/EFV 6.7 0 UD 593 – – 3
TDF/3TC/EFV 8.2 1.4 UD 457 – – 3
T1 ZDV/3TC/EFV 10.9 1.4 4.7 347 D67N (100) T69D (99)
K70R (100) M184V (100)
T215V (100)
K219Q (100)
A98G (100)
K103N (100)
V108I (2) E138G (66)
0
258b CRF02 T0 ZDV/3TC/EFV 5.2 0 UD 565 – – 3
TDF/3TC/EFV 5.8 0.6 UD 269 – – 3
TDF/3TC/EFV 6.5 1.3 5.3 238 K70E (1) M184V (3)
T215F (2)
L100I (5) K103N (96) 0.5
UD, undetectable (,40 copies/mL); D4T, stavudine; 3TC, lamivudine; NVP, nevirapine; TDF, tenofovir disoproxil fumarate; EFV, efavirenz; ZDV,
zidovudine.
aRAMs were detected by Sanger sequencing and deep sequencing. The frequency (%) of each RAM in the deep sequencing reads is reported in paren-
theses; RAMs detected only by deep sequencing are underlined.
bSubject 258 interrupted ART 2 years prior to T1; the T1 viral load and CD4 count were 5.1 log10 copies/mL and 54 cells/mm
3, respectively.
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rates reported in populations undergoing virological monitoring
than in those without routine access to viral load testing, as also
reflected in this study.10 Emphasis has been placed on providing
adherence support prior to changing ART for patients experiencing
viraemia in SSA, given that re-suppression is frequently observed.
In our cohort, it was common for viraemic patients to gain
suppression while remaining on first-line ART. However, this
was generally only true of patients that showed a viral load
Table 5. Patients on efavirenz or nevirapine showing a detectable viral load at both T0 and T1a
RAMs
ID and
subtype Timepoint Regimen
ART
(years)
TDF
(years)
Viral load
(log10 copies/mL)
CD4 count
(cells/mm3) NRTI NNRTI GSS
061 CRF02 T0 ZDV/3TC/NVP 1.0 0 1.8 126 none none 3
TDF/3TC/EFV 2.0 1.0 UD 536 – – 3
T1 TDF/3TC/EFV 5.0 4.0 1.8 306 none none 3
134 CRF02 T0 ZDV/3TC/EFV 2.5 0 1.7 284 no amplicon no amplicon 3
TDF/3TC/EFV 4.3 1.9 UD 465 – – 3
T1 TDF/3TC/EFV 6.6 4.1 4.2 435 none K101E (26) K101N (4)
K103N (39)
2
048 CRF02 T0 ZDV/3TC/EFV 3.0 0 1.6 590 none none 3
TDF/3TC/EFV 3.8 0.8 UD 515 – – 3
T1 TDF/3TC/EFV 6.8 3.8 5.5 176 none K103N (90) 2
004 CRF06 T0 ZDV/3TC/NVP 4.3 0 3.5 547 D67N (99) K70R (99)
M184V (100) T215I (5)
T215V (66) K219Q (99)
A98G (92) K101E (99)
G190A (99)
0.5
TDF/3TC/NVP 5.1 0.8 3.7 327 D67N (99) K70R (100)
M184V (100)
K219Q (100)
A98G (100) K101E (99)
K103N (1) V108I (52)
G190A (97) P225H (63)
0.5
T1 TDF/3TC/EFV 7.9 3.6 4.2 192 D67N (99) T69N (68) K70R
(99) L74I (89) M184V
(100)
T215V (99) K219Q (100)
A98G (100) K101E (73)
K103N (26) V108I (98)
G190A (100) P225H (99)
0.5
040 CRF02 T0 D4T/3TC/NVP 1.8 0 4.1 541 M184V (100) V106A (100) 1
TDF/3TC/EFV 2.4 0.6 4.0 511 K65R (80) K70E (18)
L74V (1) M184V (100)
K103N (85) V106A (100)
G190A (11)
0
TDF/3TC/EFV 2.9 0.9 5.1 386 K65R (99) Y115F (46)
M184V (100)
K103N (99)
V106A (100)
0
T1 TDF/3TC/EFV 6.0 4.1 5.6 139 K65R (100) K70T (100)
L74I (2) Y115F (100)
M184V (100)
K103N (100) V106A (100)
F227L (100)
0
101 CRF02 T0 ZDV/3TC/NVP 0.9 0 3.6 396 M184V (100) K103N (100) 1
TDF/3TC/NVP 1.5 0.8 2.0 344 no amplicon no amplicon 1
T1 TDF/3TC/EFV 4.8 3.9 4.5 269 L74I (14)
M184V (100)
A98G (2) K103N (100)
P225H (100) Y318F (1)
1
150b T0 ZDV/3TC/EFV 7.4 0 1.7 1009 no amplicon no amplicon 3
TDF/3TC/EFV 7.9 0.4 UD 870 – – 3
113c CRF02 T0 ZDV/3TC/EFV 3.0 0 4.1 591 M184V (99) L100I (88) K103N (99)
Y188L (8)
1
TDF/3TC/EFV 3.8 0.9 4.4 150 K70R (62) Y115F (1)
M184V (100)
L100I (97) K103N (99)
V108I (3) Y188L (1)
1
TDF/3TC/EFV 4.3 1.4 5.2 147 K70E (31) K70R (8) M184V
(100) T215F (74) K219E
(3) K219Q (2)
L100I (96) K103N (99)
V108I (1) Y188L (2)
0.25
UD, undetectable (,40 copies/mL); D4T, stavudine; 3TC, lamivudine; NVP, nevirapine; TDF, tenofovir disoproxil fumarate; EFV, efavirenz; ZDV,
zidovudine.
aRAMs were detected by Sanger sequencing and deep sequencing. The frequency (%) of each RAM in the deep sequencing reads is reported in paren-
theses; RAMs detected only by deep sequencing are underlined.
bSubject 150 interrupted all ART 3 years prior to T1; the T1 viral load and CD4 count were 3.9 log10 copies/mL and 238 cells/mm
3 respectively.
cSubject 113 interrupted all ART 3 months prior to T1; the T1 viral load and CD4 count were 5.0 log10 copies/mL and 40 cells/mm
3 respectively.
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,200 copies/mL or had a higher viral load but no detectable resist-
ance. Thus, the impact of adherence support is likely to be limited
with regimens that pose a low barrier to resistance, and once
NNRTI RAMs have emerged if patients receive efavirenz (or other
NNRTIs). In our study, virological outcomes were also significantly
affected by a history of treatment interruptions. One-third of
patients reported that they had interrupted ART for3 continuous
days at least once since first starting treatment, in most cases due
to the unavailability of the ART dispensary. A previous qualitative
study from the same centre in Kumasi reported that three-
quarters of patients on ART had experienced drug stock-outs and
treatment interruptions lasting for an average of 30 days.37 While
the previous study did not measure viral load outcomes, we found
that each reported episode of treatment interruption more than
doubled the risk of viral load detectability at follow-up. Thus, in
addition to general measures to support adherence, structural bar-
riers to treatment provision must be removed to optimize out-
comes and reduce loss to follow-up and mortality in SSA.38,39
A reduction of clinical visits and ART pick-ups, improving linkage be-
tween communities and clinics, community dispensing of ART and
immediate start of ART at diagnosis are proposed as viable
options.12,40–42 Providers and patients should also be alerted to the
risk of NNRTI resistance associated with abrupt ART interruptions,
due to the long half-life of efavirenz and nevirapine.43
A number of considerations apply to this study. We used viral
load detectability (.40 copies/mL) as an endpoint, rather than
applying a viral load cut-off to the definition of virological failure.2
We based this approach on our previous observation that in
Western cohorts low-level viraemia is predictive of higher viral load
rebound;17 a similar observation has been recently made for
SSA.44 However, although we attempted resistance testing at all
detectable viral loads, both sequencing success and detection of
resistance were higher at viral load .200 copies/mL. A further
point relates to the clinical significance of the observed NRTI resist-
ance patterns. Recent studies in SSA have indicated that genotypic
resistance testing might not accurately predict NRTI activity during
PI-based second-line ART.45 Interestingly, detection of NRTI resist-
ance, most commonly M184V and TAMs, was found to predict sig-
nificantly higher (rather than lower) odds of virological suppression
on second-line ART.10 One proposed explanation is that patients
who develop resistance at failure of first-line ART may have higher
levels of adherence (hence higher drug selective pressure) than
Table 6. Patients that introduced lopinavir/ritonavir between T0 and T1a
RAMs
ID and
subtype Timepoint Regimen
ART
(years)
TDF
(years)
Viral load
(log10 copies/mL)
CD4 count
(cells/mm3) NRTI NNRTI GSS
020 CRF02 T0 ZDV/3TC/NVP 3.9 0 3.5 161 K70R (2) M184V (100) K101E (99) G190A (100) 1
TDF/3TC LPV/r 4.8 0.8 3.1 61 no amplicon no amplicon 2
T1 TDF/3TC LPV/r 8.1 4.2 UD 270 – – 2
127 T0 ZDV/3TC/NVP 3.8 0 UD 175 – – 3
TDF/3TC LPV/r 5.2 1.3 UD 215 – – 3
T1 TDF/3TC LPV/r 8.5 4.7 2.0 391 no amplicon no amplicon 3
082 CRF06 T0 D4T/3TC/NVP 2.4 0 4.6 306 D67N (2) M184V (100)
T215Y (99)
Y181C (99) 1
TDF/3TC EFV 4.4 2.0 2.9 36 M184V (72) T215Y (74) K101E (16) K101Q (9)
K103N (7) V108I (58)
Y181C (74) G190A (58)
1
T1 TDF/3TC ZDV LPV/r 6.5 4.1 1.8 287 M184V T215Y V108I Y181C G190A 2.25
186 CRF02 T0 ZDV/3TC/EFV 4.4 0 4.8 109 M184V (100) K103N (22) V106A
(80)V108I (81) M230L
(78)
1
TDF/3TC/EFV 5.0 0.6 4.2 231 M184V (100) V108I (100) H221Y (56)
M230L (100)
1
TDF/3TC/EFV 5.5 1.2 4.6 64 K65R (88) T215F (5)
M184V (100)
V108I (99) H221Y (12)
M230L (99)
0
T1 TDF/3TC ZDV LPV/r 8.3 3.9 2.1 337 K65R K70T M184V V108I M230L 1.5
016 T0 D4T/3TC/EFV 4.2 0 UD 177 – – 3
TDF/3TC LPV/r 5.3 1.1 UD 288 – – 3
T1 TDF/3TC LPV/r 7.9 3.7 UD 463 – – 3
UD, undetectable (,40 copies/mL); D4T, stavudine; 3TC, lamivudine; NVP, nevirapine; TDF, tenofovir disoproxil fumarate; EFV, efavirenz; ZDV,
zidovudine.
aAt T0 and intermediate timepoints RAMs were detected by Sanger sequencing and deep sequencing. The frequency (%) of each RAM in the deep
sequencing reads is reported in parentheses; RAMs detected only by deep sequencing are underlined. At T1 RAMs were detected by Sanger sequenc-
ing alone; protease sequences were also obtained at T1 and showed no major RAMs.
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subjects who fail without resistance. Furthermore, it is well estab-
lished that NRTIs such as tenofovir and zidovudine retain signifi-
cant residual antiviral activity in the presence of TAMs, and that
this is enhanced by the concomitant presence of M184V and con-
tinuation of lamivudine.46 There is currently scarce evidence that
similar principles apply to populations with multiple discriminatory
NRTI RAMs, and the benefit of continuing tenofovir and lamivudine
in such populations remains to be demonstrated. In addition, the
high viral loads associated with the observed mutation profiles
raise concerns about clinical progression, while potential onward
transmission of tenofovir RAMs may impact both treatment and
pre-exposure prophylaxis programmes. In this scenario, it has
been argued that the most cost-effective strategy to prevent
transmission of resistance lies in a prompt switch to second-line
ART.47 Further studies are needed to optimize the adoption of viral
load monitoring and strategies for use of second-line ART in the
region.
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